Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr David Jamieson.

Newcastle AuthorsTitleYearFull text
Dr Shelby Barnett
Julie Errington
Julieann Sludden
Dr David Jamieson
Professor Gareth Veal
et al.
Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population2021
Swathi Merugu
Dr Lindi Chen
Elizabeth Gavens
Hany Gabra
Dr Al Gabriel
et al.
Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers2020
Marian Case
Dr Dino Masic
Dr David Jamieson
Dr Frederik van Delft
Dr Andrew Filby
et al.
Label-Free Leukemia Monitoring by Computer Vision2020
Suriyon Uitrakul
Dr Claire Hutton
Professor Gareth Veal
Dr David Jamieson
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells2019
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Jane Margetts
Laura Ogle
Dr Anthony Chan
Dr David Jamieson
Dr Catherine Willoughby
et al.
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?2018
Professor Gareth Veal
Dr David Jamieson
Katja Kuver
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial2017
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Professor Edvaldo Ribeiro Rosa
Dr Deepali Pal
Dr David Jamieson
Dr Kenneth Rankin
Dr Matthew Benning
et al.
Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Patterson
Dr David Jamieson
et al.
Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)2016
Dr David Jamieson
Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability2016
Professor Gareth Veal
Julieann Sludden
Dr David Jamieson
Julie Errington
Dr Ghada Malik
et al.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma2016
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al.
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Dr Catherine Willoughby
Dr Claire Hutton
Dr Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?2016
Angharad Humphreys
Dr Al Gabriel
Dr Nicholas Bown
Dr Lindi Chen
Dr David Jamieson
et al.
Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Dr Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Morton
Liam Bolt
Dianne Turner
et al.
The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained2016
Dr Sheba Macheka
Dr David Jamieson
Professor Helen Reeves
Misti McCain
The isolation and characterisation of circulating tumour cells from patients with hepatocellular carcinoma2016
Barry Dent
Dr Rachel O'Donnell
Laura Ogle
Padmini Ramesh
Nick Hayes
et al.
Detection and characterization of circulating tumor cells by imaging flow cytometry2014
Dr Laura Ogle
Dr David Jamieson
Dr Rachel O'Donnell
Barry Dent
Professor Nicola Curtin
et al.
Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStreamx2014
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Dr Celine Cano
et al.
Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity2014
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Christopher Hill
Dr David Jamieson
Huw Thomas
Dr Colin Brown
Professor Alan Boddy
et al.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo2013
Dr Rachel O'Donnell
Barry Dent
Laura Ogle
Professor Nicola Curtin
Dr David Jamieson
et al.
The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream2013
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Niu Tan
et al.
The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells2013
Professor Ann Daly
Professor Gareth Veal
Dr David Jamieson
Dr Sally Coulthard
Pharmacogenomics research at Newcastle University2012
Dr Jane Renwick
Shaun Martin
Nicola Illingworth
Dr David Jamieson
Professor Penny Lovat
et al.
The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide2012
Dr Sophie Weatherhead
Professor Peter Farr
Dr David Jamieson
Dr Jennifer Hallinan
Dr James Lloyd
et al.
Apoptosis of keratinocytes is a key mechanism in UVB-induced clearance of psoriasis2011
Dr Sophie Weatherhead
Professor Peter Farr
Dr David Jamieson
Dr Jennifer Hallinan
Dr James Lloyd
et al.
Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation2011
Dr David Jamieson
Professor Alan Boddy
Pharmacogenetics of genes across the doxorubicin pathway2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Dr Nicola Cresti
Dr David Jamieson
The pharmacology of trastuzumab and its use in breast cancer2010
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma2009
Dr Sophie Weatherhead
Dr David Jamieson
Professor Nick Reynolds
Real time imaging of UVB-induced keratinocyte apoptosis, and analysis of factors influencing cell-to-cell variation2009
Dr Sophie Weatherhead
Dr David Jamieson
Professor Nick Reynolds
Real-time imaging of ultraviolet B-induced keratinocyte apoptosis to determine duration of apoptosis and effect on tissue turnover2009
Dr David Jamieson
Mitomycin C2008
Dr David Jamieson
Kerrie Wilson
Dr Simon Pridgeon
Dr Jane Margetts
Professor Richard Edmondson
et al.
NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism2007
Dr David Jamieson
Professor Alan Boddy
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor2006